

**Anti-diabetic Effect of the Methanolic Leaf Extract of  
*Axonopus Compressus* (P. Beauv) in Alloxan Induced  
Diabetic Rats**

**ABSTRACT**

**Aims:** This study is a preliminary step in investigating the anti-diabetic effect of the methanolic extract of the leaf of *Axonopus Compressus* (P. Beauv) in alloxan-induced diabetic rats.

**Study design/Methodology:** Intraperitoneal (i.p.) injection of alloxan monohydrate at the dose of 180mg/kg b.w was carried out to induce diabetes in the rat models. Different doses (250, 500 and 1000mg/kg b.w.) of the extract was administered per oral through gastric gavage to the alloxan induced diabetic rats, and 2mg/kg b.w. of glibenclamide was used as the standard drug, and only tween 20 solution (10 ml/kg) given to the negative control group. AccuCheck Active® (an auto-analyzer) glucose kit was used to assay the effects of the P. Beauv extract and the standard drug on the fasting blood glucose level at 0, 1, 3 and 6 h using the blood collected through the snip made in the tail of the rats.

**Results:** the different doses of 250, 500 and 1000 mg/kg b.w. produced a significant ( $p < 0.05$ ) reduction in the blood glucose level of the alloxan-induced diabetic animal models in the degree of 31.5%, 19.8% and 24.5% respectively, compared to the negative control group and this was time dependent (at the end of the 6<sup>th</sup> hour, although a decrease in the blood glucose was also noticed at the 1st, 3rd hours). 2 mg/kg glibenclamide decreased the blood glucose levels by 69.9% while the blood glucose level of the negative control group increased by 15.2% at the 6th hour.

**Conclusion:** it is obvious from the above findings that that *Axonopus compressus* deserves further investigations into the active ingredients and structural elucidation to validate the anti-diabetic property it possess.

**Keywords:** *Axonopus compressus*, Alloxan, Diabetes, glibenclamide

**1. INTRODUCTION**

A quick review of evaluations and projections by the World Health Organization suggests that, in 2014 the global prevalence of diabetes had an estimate of 9% among adults (18 years and above) [1]. In 2012, about 1.5 million deaths were estimated to be directly caused by diabetes, with over 80% of those deaths occurring in the low- and middle-income countries [2], and that diabetes will rank the 7th leading cause of death in 2030 [3]. Diabetes is a major degenerative disease in the world today, affecting at least 15 million people and having complications which include hypertension, atherosclerosis and microcirculatory disorders [4]. However it is the most common endocrine disorder that impairs glucose homeostasis resulting in severe diabetic complications including retinopathy, nephropathy and also causing neurological disorders due to perturbation in glucose uptake [5]. It is a chronic disease characterized by high blood glucose levels due to inability of the beta cells of the islets of Langerhans in the pancreas to produce insulin, leading to insulin deficiency or as a result of defective responsiveness of insulin receptors at the body tissues to insulin. Currently available therapy for diabetes include insulin and various oral antidiabetic agents such as sulphonylureas, metformin,  $\alpha$ -glucosidase inhibitors, and

28 troglitazone [6]. These drugs are used as mono-therapy or in combination to achieve better glycemic  
29 control. The use of the above oral agents causes a number of serious adverse effects which includes  
30 digestive disorders (nausea, vomiting, cholestase), blood disorders (hemolytic anemia), and  
31 hypoglycemia. As a consequence there continues to be the high demand for new oral anti-diabetic drug  
32 with little or no side effect. Plants are well known in traditional herbal medicine for their hypoglycemic  
33 activities and available literatures indicate that there are more than 800 plant species showing  
34 hypoglycemic activity [7]. There has been increasing demand for the use of plant products with anti-  
35 diabetic activity due to its low cost, easy availability and less side effects. Therefore, plant materials are  
36 continuously scrutinized and explored for their effects as hypoglycemic agents. *Axonopus compressus*  
37 (*P.Beaux*) also known as carpet grass is a plant that is widely spread in most parts of Nigeria and used as  
38 forage for animals. Also it is been found that *Axonopus compressus* (*P.Beaux*) is prescribed to common  
39 cold and diabetic patient in folklore medicine, necessitating the idea that *Axonopus Compressus* may  
40 have anti-diabetic property hence this property shall be investigated by carrying out this study.

41

## 42 2. MATERIAL AND METHODS / METHODOLOGY

43

44 Fresh leaves of *Axonopus compressus* were collected from natural habitat in Micheal Okpara University of  
45 Agriculture Umudike in the month of June 2010. Their botanical identity was confirmed by Dr Dike of  
46 forestry department, college of Natural Resources and Environmental management, Micheal Okpara  
47 University of Agriculture Umudike Nigeria. The leaves were washed with distilled water without squeezing  
48 to remove debris and dust particles. The leaves were dried at room temperature and they were pulverized  
49 with manual blender. 92.35 grams of the powdered leaves was cold macerated in 80% methanol for 48  
50 hours with intermittent shaking every two hours. The extract material was filtered with Whatmann filter  
51 papers No 1 into a weighed beaker. The obtained crude extract was stored in a beaker in a refrigerator  
52 below 10°C until time of use. Adult male wistar albino rats (120 ±20g) and mature albino mice of both  
53 sexes (22±6g) were used throughout the experiments. The animals were procured from the laboratory  
54 animal unit of faculty of veterinary Medicine, University of Nigeria, Nsukka. The animals were allowed to  
55 acclimatize to the environment for a period of 7 days before the start of the experiment. Standard  
56 environmental conditions such as temperature (28±1c) and relative humidity (46 ± 6%) with 12 hour light-  
57 dark cycle and adequate ventilation were maintained in the animal house. The animals were kept in  
58 plastic cages and commercial pelleted feed (Vital Feed ® Nigeria). Ethical conditions governing the  
59 conducts of the experiment with life animals as stipulated by Ward and Elsea [8] were strictly observed.

### 60 2.1 Grouping of the Animals

61 Twenty-five adult male wistar albino rats were weighed using citizen electronic weighing balance and  
62 randomly grouped into five groups (A –E) of five rats per group.

### 63 2.2 Anti-Diabetic Study

64 The study was carried out using the method described by Venogopal *et al*, [9] with slight modifications.  
65 The fasting blood glucose level of the adult albino rats were measured with an autoanalyzer (AccuCheck  
66 Active (®)) glucose kit after an overnight fast with water made available to them. Diabetes was then  
67 induced in the rats by single intraperitoneal injection of alloxan monohydrate dissolved in distilled water at  
68 the dose of 180 mg/kg b.w. The fasting blood glucose level of each of the rats were checked from the 5<sup>th</sup>  
69 day. After 8 days, animals with fasting blood glucose levels of 250 mg/dl and above were considered to  
70 be diabetic and were used for the study.

### 71 2.3 Study Design

72 The rats were randomly regrouped into five groups of five rats each.

73 Group A – served as the negative control and received tween 20 solution (solvent used to dissolve the  
74 extract) 10 ml/kg..

75 Group B – received the extract at the dose of 250 mg/kg b.w.

76 Group C – received the extract at the dose of 500 mg/kg b.w.

77 Group D – received the extract at the dose of 1000 mg/kg b.w.

78 Group E – served as the positive control and received glibenclamide the standard reference drug at the  
79 dose of 2 mg/kg b.w.

### 80 2.4 Fasting Blood Sugar Test

81 Blood samples from the tail snip was used to measure the blood glucose levels using AccuCheck Active  
82 (®)autoanalyzer and glucose test strips (GCO1465997, Roche Diagnostic Mannheim, Germany). The

83 fasting blood glucose level of the rats were determined at zero hour before oral administration of drug and  
84 extracts and then determined at 1, 3 and 6 hours in each case after drug and extract administration.

85  
86 **2.5 Statistical Analysis**

87 Results were presented as mean  $\pm$  standard error of mean (SEM) and the statistical analysis was done  
88 using one way analysis of variance (ANOVA). The differences between the mean were tested using Post  
89 Hoc LSD. A p-value of  $p < 0.05$  was considered to be statistically significant.

90  
91 **3. RESULTS AND DISCUSSION**

92  
93 Table 1: Mean blood glucose levels during a preliminary anti-diabetic study of the leaf extracts of  
94 *axonopus compressus* in alloxan induced diabetic rats.

95

		Fasting blood glucose level mg/dl			
96	Group Treatment	0 hour	1 hour	3 hour	6 hour
97	A) Alloxan + Tween 20	393.0 $\pm$ 5.7	457.6 $\pm$ 6.2	452.2 $\pm$ 5.7	463.6 $\pm$ 5.5
98	B) Alloxan + ACE (250mg/kg)	331.6 $\pm$ 5.9	271.0 $\pm$ 4.3	265.2 $\pm$ 4.9*	227.2 $\pm$ 3.4*
99	C) Alloxan + ACE (500mg/kg)	430.2 $\pm$ 5.7	379.6 $\pm$ 4.2	356.2 $\pm$ 4.1	255.4 $\pm$ 6.5*
100	D) Alloxan + ACE (1000mg/kg)	342.2 $\pm$ 5.0	268.4 $\pm$ 4.4	298.0 $\pm$ 5.0*	258.4 $\pm$ 4.4*
101	E) Alloxan + Glibenclamide	308.2 $\pm$ 1.8	168.8 $\pm$ 1.4*	116.0 $\pm$ 0.7*	92.6 $\pm$ 1.3*
102					

103 Values are postprandial blood glucose levels in each group expressed as Mean  $\pm$  SEM; n = 5 animals in each group; P < 0.05 is  
104 considered significant when compared with the untreated alloxan induced diabetic rats in control group (using one way analysis of  
105 variance).

106  
107 Alloxan is one of the usual substances used for the induction of type 1 diabetes mellitus apart  
108 from streptozotocin. Alloxan has a destructive effect on the beta cells of the pancreas [10]. It causes a  
109 massive reduction in insulin release by the destruction of beta cells of the islets of Langerhans, thereby  
110 inducing hyperglycemia which is characteristically similar to type 1 diabetes in human [11]. In the present  
111 study, hypoglycemic activity of the methanolic extract of *A. compressus* leaves was evaluated in alloxan-  
112 induced diabetic rats by testing its effect on fasting blood glucose level using Accu-check active  $\text{\textcircled{R}}$  auto  
113 analyzer glucometer kit. The extract was given at the doses of 250, 500, and 1000 mg/kg b.w. to the  
114 alloxan induced diabetic rats while glibenclamide (2mg/kg) was used as standard reference drug and the  
115 negative group was given only the tween 20 (solvent) solution at the dose of 10 ml/kg after induction of  
116 diabetes. From the results of this work, methanolic leaf extract of *Axonopus compressus* at all the doses  
117 (250, 500 and 1000 mg/kg) used caused a respective time dependent and significant ( $p < 0.0001$ )  
118 reduction (by 31.5%, 19.8% and 24.5%) of the blood glucose levels in the diabetic rats when compared to  
119 the negative control group at the 6th hour. Glibenclamide, the reference drug used in carrying out this  
120 study produced a better significant reduction in the fasting blood glucose level of the alloxan induced  
121 diabetic rats when compared to the extract. Glibenclamide belongs to the class of oral hypoglycemic  
122 agents called sulphonylureas. Sulphonylureas functions by inhibiting ATP-sensitive K<sup>+</sup> channels leading  
123 to a reduced efflux of potassium concentration. This will create a sufficient cellular depolarization which  
124 will cause the opening of the voltage-dependent calcium channels. It is the increase in intracellular Ca<sup>2+</sup>  
125 that causes insulin secretion [12]. Sulphonylureas also functions to inhibit glucagon secretion and  
126 sensitize target tissues to the action of insulin [12]. Plant extract that reduces blood sugar level has been  
127 suggested to have an antidiabetic activity and could be acting like a drug [13, 14]. The result of this study  
128 shows that the extract reduced the fasting blood glucose level of the alloxan induced diabetic rats. This  
129 suggest that *A. compressus* extract could stimulate insulin secretion from the remnant beta-cells or from

130 regeneration beta-cells like the reference drug. According to J. C. Harborne 1998 and Arika et al, 2015  
131 [15,16], plants are known to possess various phytochemicals which are potent in ameliorating various  
132 diseases and infections such as diabetes so one could suggest that the hypoglycemic activity of the  
133 extract could be as a result of a synergistic effect of the phytochemicals inherent in the plant. Also mineral  
134 elements such as Magnesium, potassium, Calcium, Manganese, Iron, Zinc, Chromium, Copper, and Vanadium  
135 have been implicated to contribute to the antidiabetic effect of most antidiabetic medicinal plants due to their function  
136 in most metabolic pathways of the body [17], so I could say that the antidiabetic properties of *Axonopus*  
137 *compressus* could be as a result of the mineral elements contained in them. Moreso, the reduction in the  
138 fasting blood glucose level in alloxan- induced diabetic rats in this study could suggest that the extract  
139 might have worked via several mechanisms such as slowing down absorption of sugar from the gut,  
140 decreasing the release of glucose by the liver, or increasing glucose uptake by the fat and muscle cells  
141 [18] [19].  
142

## 143 CONCLUSION

144 This proposed mechanism of action may await further studies for its authentication. Also, an estimation of  
145 insulin level, insulin receptor and other biochemical parameters can give an insight into the mechanism of  
146 the anti-diabetic activity exhibited by the extract. However, the findings suggest that *Axonopus*  
147 *compressus* may possess antidiabetic property.  
148

## 149 REFERENCES

- 150  
151  
152 1. Global status report on noncommunicable diseases 2014. Geneva, World Health Organization,  
153 2012.
- 154  
155 2. World Health Organization. Global Health Estimates: Deaths by Cause, Age, Sex and Country,  
156 2000-2012. Geneva, WHO, 2014.
- 157  
158 3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030.  
159 *PLoS Med*, 2006, 3(11):e442.
- 160  
161 4. Edem, D. O., (2009). Hyperglycemic Effect of Ethanolic Extract of Alligator pear seed (*Persea*  
162 *Americana* Mill) in Rats. *European Journal of scientific Research*, 33(4), 669-678
- 163  
164 5. Vivek, K. S., Suresh, K., Hitesh, J. P., and Schivakumar, H., (2010). Hypoglycemic activity of *Ficus*  
165 *glomerata* in Alloxan-induced diabetic rats. *International Journal of Pharmaceutic Sciences Review and*  
166 *Research*, 1(2):18-22.
- 167  
168 6. Kameswararao, B., Kesavulu, M.M. and Apparao, C. (2003). Evaluation of antidiabetic effect of  
169 *Momordica cymbalaria* fruit in alloxan-diabetic rats. *Fitoterapia*. 74:7-13.
- 170  
171 7. Rajagopal, K. and Sasikala, K., (2008). Anti-hyperglycemic and Anti-hyperlipidemic effects of  
172 *Nymphaea steudata* in alloxan-induced diabetic rats. *Singapore Medical Journal*, 49:137-141.
- 173  
174 8. Ward, J. W., and Elsea, J. R. (1997). *Animal case and use in drug rate and metabolism, methods*  
175 *and techniques*, volume II, editors Edward R. G., Jean, L. H., Marcel, D., New York 1997. Pp 372-390.
- 176  
177  
178 9. Venegopal, P. M., Prince, P. S. M. and Pari, L. (1998). Hypoglycemic activity of *Syzygium cumini*  
179 seeds: Effects on lipid peroxidation in alloxan-induced diabetic rats. *Journal of Ethnopharmacology*, 61:1-7
- 180  
181 10. Jelodar, G., Mohsen, M., Shahram, S., (2003). Effect of Walnut leaf, coriander and pomegranate  
182 on blood glucose and histopathology of pancreas of alloxan-induced diabetic rats. *African Journal of*  
183 *Traditional, Complementary and Alternative Medicines*, (3) 229-305.
- 184  
185

- 186 11. Szkudelski, T. (2001). The mechanism of alloxan and streptozotocin actions in beta cells of rat  
187 pancreas. *Physiological Research*. **50**: 536-546  
188
- 189 12. Wadkar, K. A., Magdun, C. S., Patil, S. S. and Naikwade, N. S. (2008). Antidiabetic potential and  
190 Indian medicinal plants. *Journal of Herbal Medicine and Toxicology*. **2**(1): 45-50.  
191  
192
- 193 13. Venkatesh S., Reddy D. G., Reddy B. M., Ramesh M., and Appa Rao A. V. N. (2003),  
194 Antihyperglycemic activity of *Caralluma attenuata*. *Fitoterapia* **74**, 274D279.  
195
- 196 14. Adikwu, M. U., Uzuegbu, D. B., Okoye, T. C. Uzor, P. F., Adibe, M. O., Amadi, B., (2010). Anti-  
197 diabetic effect of combined aqueous leaf extract of *Venonia Amygdalina* and Metformin in rats. *Journal of*  
198 *basic and clinical pharmacy*, 1(3).  
199  
200
- 201 15. Harborne, J. B. (1998). *Phytochemical methods: A guide to modern techniques of plant analysis*.  
202 3<sup>rd</sup> Edn. Chapman and Hall, London, pp. 1-3.  
203  
204
- 205 16. Arika, W. M., Abdirahman, Y. A., Mawia, M. M., Wambua, K. F., Nyamai, D. M., Ogola, P. E.,  
206 Kiboi, N. G., Nyandoro, H. O., Njagi, S. M., Agyirifo, D. S., Ngugi, M. P., and Njagi, E. N. M. (2015).  
207 Hypoglycemic Effect of *Lippia javanica* in Alloxan Induced Diabetic Mice. *Journal of Diabetes and*  
208 *Metabolism*, **6** (11): 624-630.  
209
- 210 17. Arika, W. M., Ogola, P. E., Nyamai, D. W., Mawia, A. M., Wambua, F. K., Kiboi, N. G., Wambani,  
211 J. R., Njagi, S. M., Rachuonyo, H. O., Emmah, K. O., Lagat, R. C., Muruthi, C. W., Abdirahman, Y. A.,  
212 Agyirifo, D. S., Ouko, R. O., Ngugi, M. P. and Njagi, E. N. M. (2016), Mineral Elements Content of  
213 Selected Kenyan Antidiabetic Medicinal Plants. *Advanced Techniques in Biology & Medicine*, **4**(1):1-6.
- 214 18. Grover, J. K., Vat, V., Rathi S.S., (2000). Antihyperglycemic effect of *Eugenia Jambolana* and  
215 *Tinopora cordifolia* in experimental diabetes and their effect key metabolic enzymes involved in  
216 carbohydrate metabolism. *Journal of Ethnopharmacology*. (73) 616-470.
- 217 19. Ibeh BO Ezeaja MI. Preliminary study of antidiabetic activity of the methanolic leaf extract of  
218 *Axonopus compressus* (P. Beauv) in alloxan-induced diabetic rats. *J thnopharmacol*. 2011 Dec 8;  
219 138(3):713-6